Neurology Central

Reports of brain damage call a halt to Bellicum trials: industry news round-up

Pharmaceutical policy announcements, promising drug trial data and more: check out our round-up of the biggest news from the neuroscience and neurology industry this week.
Our pick of the headlines this week:
  • Bellicum Pharmaceuticals forced to halt drug trials after three cases of brain damage reported
  • Positive results from Phase III eslicarbazepine acetate epilepsy trial
  • Pfizer confirms cull of neuroscience programs
  • Sunovion announce Phase III Parkinson’s trial results for apomorphine
  • Sage Therapeutics present findings from latest investigation into insomnia drug
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.